Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Aerovate's (AVTE) shares plunge 93% as its lead candidate, AV-101, fails to meet the primary and secondary endpoints in the phase IIb/III study to treat pulmonary arterial hypertension patients.
Peter Garcia, Chief Financial Officer of ALX Oncology Holdings Inc (NASDAQ:ALXO), purchased 12,000 shares of the company on June 13, 2024, as reported in a recent SEC Filing.